Who is sponsoring NCT04082351?

NCT04082351 is sponsored by ALI KAMAL M. SAMI.

What drugs are being tested in NCT04082351?

Interventions in NCT04082351: Nanotechnology structured water ( Magnalife), ordinary water.

What condition does NCT04082351 study?

NCT04082351 studies Type2 Diabetes.

Is NCT04082351 still recruiting?

NCT04082351 is currently completed. Last updated 10 September 2019.

Last reviewed 2019-09-10 · How we verify

NCT04082351

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.

Completed NA Last updated 10 September 2019

What this trial tests

NA trial testing Nanotechnology structured water ( Magnalife) in Type2 Diabetes in 387 participants. Completed in 16 February 2018.

Timeline

3 July 2016

Primary endpoint
16 February 2018

16 February 2018

Quick facts

Lead sponsor	ALI KAMAL M. SAMI
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	387
Start date	3 July 2016
Primary completion	16 February 2018
Estimated completion	16 February 2018

Drugs / interventions tested

Nanotechnology structured water ( Magnalife)
ordinary water

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

ALI KAMAL M. SAMI — full company profile →

Who can join

Eligibility, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 2 DM is due to insulin resistance or low insulin secretion or sometimes a combination of both. Nanotechnology structured water is a type of water that is produced using energy field modulators to change the biological, chemical, and physical properties of water molecules and improve the bioavailability of this nano-water. Objective: To find out the effect of drinking nanotechnology structured water (Magnalife®) on the blood glucose levels in patients with type 2 diabetes mellitus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.
Huang Y, Guo X, Wu Y, Chen X, et al · · 2024 · cited 188× · PMID 38378653 · DOI 10.1038/s41392-024-01745-z

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other ALI KAMAL M. SAMI trials

Trials by the same sponsor.

NCT07507591 — Safety, Efficacy, and Short-Term Outcomes of Rezūm Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia Under Lo · completed
NCT06677177 — The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms · NA · completed
NCT06681116 — Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04082351 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ALI KAMAL M. SAMI
Last refreshed: 10 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04082351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing